ACTU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACTU is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is showing a modest short-term rebound, but there is no clear technical breakout, no supportive options signal, no recent news catalyst, and the latest financials still show losses with declining EPS. Analyst sentiment remains positive overall, but the reduced price target suggests tempered expectations. My direct view: hold off on buying now and wait for a stronger setup.
ACTU closed at 3.01 after a 2.08% regular-session gain, which is constructive in the very short term. However, the MACD histogram is positive but contracting, suggesting momentum is fading rather than accelerating. RSI at 65.47 is neutral-to-bullish but not oversold, so there is no obvious bargain signal. Moving averages are converging, which usually points to consolidation rather than a confirmed trend. Price is sitting just below resistance at 3.081 (R1), with pivot support at 2.665. The current structure suggests range-bound trading, not a clean long-term entry. The stock trend model also implies limited near-term upside.
["H.C. Wainwright kept a Buy rating on the stock.", "The shares had a positive regular-session move and closed above the previous close.", "MACD remains above zero, indicating the recent trend is still mildly constructive."]
["No news in the past week, so there is no fresh event-driven catalyst.", "Analyst price target was cut to $15 from $20, signaling reduced near-term upside expectations.", "Latest quarter showed a net loss of -$4.55M and EPS decline, which weakens fundamental momentum.", "Insider and hedge fund activity is neutral with no significant buying signal.", "No congress trading data is available.", "No AI Stock Picker signal today and no recent SwingMax signal."]
In 2025/Q4, Actuate Therapeutics reported revenue of 0, unchanged year over year, so there is no visible sales growth yet. Net income fell to -4,553,953, down 29.35% YoY, and EPS dropped to -0.19, down 38.71% YoY. Gross margin was 0, reflecting a pre-revenue or non-commercial stage profile. Overall, the latest quarter shows continued loss-making operations with no growth traction in revenues.
Wall Street sentiment is still supportive but less aggressive than before. On 2026-04-13, H.C. Wainwright lowered its price target on ACTU to $15 from $20 while maintaining a Buy rating after the Q4 report. That indicates pros still see upside, but their enthusiasm has softened. The bull case is the maintained Buy rating and meaningful target upside versus the current price. The bear case is the lower target, lack of recent news, and weak financial progress.
